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Abstract The Btg family of anti-proliferative gene products
includes Pc3/Tis21/Btg2, Btg1, Tob, Tob2, Ana/Btg3, Pc3k and
others. These proteins are characterized by similarities in their
amino-terminal region: the Btg1 homology domain. However,
the pleiotropic nature of these family proteins has been observed
and no common physiological function among family members
was suggested from the history of their identification. Recent
progress in the search for Btg family functions has come from the
analysis of cell regulation and of cell differentiation. It is now
emerging that every member of this family has a potential to
regulate cell growth. We would like to propose here to use a
nomenclature APRO as a new term for the family. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The control of the cell cycle plays an essential role in cell
growth and in the activation of important cellular processes.
A large number of signaling molecules are involved in medi-
ating extracellular signals to the control of cell cycle. Among
them, it is well known that retinoblastoma protein (Rb) and
p53 are key regulators of the cell cycle progression or cell
apoptosis. Increasing evidence indicates that loss of function
of these tumor suppressor genes represent a major route to
tumor development. However, characterization of other phys-
iologically important anti-proliferative genes such as cyclin-
dependent kinase inhibitors was also achieved.
In 1991, the Pc3 gene and Tis21 gene were reported as
immediate early genes induced in rat PC12 cell line during
neuronal di¡erentiation by nerve growth factor (NGF), and
in mouse 3T3 cell line by the tumor promoter tetradecanoyl
phorbol acetate, respectively [1,2]. In the following year, mo-
lecular characterization of a chromosomal translocation ob-
served in a lymphoid malignancy resulted in the Btg1 cloning
[3], a distinct but close homologous gene to the Pc3/Tis21.
Furthermore, a third member (termed Tob) of this gene family
was identi¢ed as a binding molecule to ErbB2, a receptor
tyrosine kinase [4]. Although the respective approaches to
discover the genes/molecules were di¡erent, a biological com-
mon feature of these gene products was their ability to inhibit
cell proliferation. From that time on, other novel related
genes were also isolated over the past years using di¡erent
cloning strategies [5^10]. Since no homology to known func-
tional motifs is evident in their protein sequences of them, it
appears likely that these molecules belong to a novel func-
tional class of cell cycle regulators. In this review we will focus
on the family members and discuss the parallels and di¡er-
ences among them.
Before entering the main subject, we should put terms of
the family in order, for a smooth understanding of the con-
text. More than 20 members of this family have been found
from several species by a lot of laboratories. However, six
distinct proteins of the family have been identi¢ed in human
cells at present. Some of the designations are now a little bit
apart from the original concept of the name and might be
confusing. Accordingly, we would propose and use a united
term, which is now being introduced to the nomenclature
committee (UK), hereafter in this article. The name of
APRO is derived from the consensus function of the gene
family as ‘anti-proliferative’. The six human APRO family
proteins might be subgrouped into three classes as shown in
Fig. 1. Each two members have close amino acid sequence
similarities.
2. Structure, expression and localization
Many proteins contain motifs or regions that may be con-
sidered as building blocks, representing structural elements or
functional domains. Based of the presence of this structural
element concept, it is easily imagined that APRO proteins
may constitute a certain family. The APRO homology domain
can be divided in two short, relatively more conserved ele-
ments, box A and box B, separated by a spacer sequence of
non-conserved amino acids. This molecular organization is
reminiscent of pocket proteins such as Rb and Bcl2, which
are involved in certain signal transductions through protein^
protein interaction [6]. Both APRO5 and APRO6 contain a
predicted nuclear localization signal in this region. APRO
gene family often contains some copies of ATTTA motif
that is known as the most common determinant of the
RNA stability in mammalian cells. It should be noted that
mRNA degradation is in£uenced by many exogenous factors
such as TPA and calcium ionophores. APRO proteins seem to
be very labile. It has been shown that APRO1 and APRO2 are
expressed early during the G0/G1 transition phase of the cell
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 4 3 6 - X
*Corresponding author. Fax: (81)-52-735-8167.
E-mail: smatsuda@med.nagoya-u.ac.jp
FEBS 24862 17-5-01
FEBS 24862 FEBS Letters 497 (2001) 67^72
cycle [3,11]. This expression decreases quickly as the cells
progress through the cell cycle.
These proteins are involved in cell growth control in various
cells such as T lymphocytes, ¢broblasts, epithelial cells and
neuronal cells. These functional speci¢city and selectivity of
the di¡erent members of the family might be achieved by the
interaction with di¡erent cellular targets. For example,
APRO1 and APRO2 interact with PRMT1 (protein arginine
methyltransferase of type 1), an arginine N-methyltransferase
that plays an important role in their anti-proliferative func-
tion, and modulate its activity positively [12,13,50] ; APRO1,
APRO2 and APRO5 can also interact with Caf1 (a homolog
of the yeast Caf1/Pop2 that is a component of the CCR4
complex), which regulates the expression of a number of genes
involved in cell cycle regulation and progression [14]; APRO6
can associate with the ErbB2 growth factor receptor; and a
recent report shows that APRO6 interacts with Smad pro-
teins. These interactions will be discussed further in Section 4.
The APRO homology proteins have been found in organ-
isms from nematodes to humans with phylogenetically well-
conserved homology [15] (Fig. 2). In particular, on the basis
of the designations as proposed above, six of the structurally
de¢ned human APROs are mentioned in Figs. 1, 2 and 3.
Searching human genome sequences, it seems likely that no
more member of the APRO family exists in human genome.
The ordinal number of APRO is then numbered due to the
length of predicted protein. According to the claim of the
referenced paper, APROs could be annotated brie£y as fol-
lows.
2.1. APRO1 (Pc3, Tis21, Btg2)
It was initially described as an immediate early gene in-
duced by tumor promoters and growth factors in PC12 and
Swiss 3T3 cells [1,2,16]. Pc3, Tis21 and Btg2 are cognate genes
from rat, mouse and human, respectively. It was then proved
that APRO1 and APRO4 were of the primary responsive
genes super-induced by TPA [17], and that the expression is
also regulated by redox changes [17]. The mRNA is 2.6 kb
long. APRO1 is endowed with anti-proliferative activity and
shares signi¢cant sequence homology to APRO2. In stable
NIH3T3 clones expressing APRO1, the transition from G1
to S phase was impaired [18]. This gene is expressed in a
variety of cell and tissue types and encodes a remarkably
labile protein [19^21]. It is noteworthy that APRO1 expres-
sion is up-regulated by p53 after DNA damage induced by
genotoxic agents, suggesting that APRO1 function may be
relevant to cell cycle control and cellular response to DNA
damage [11].
2.2. APRO2 (Btg1)
APRO2 is also essentially expressed in quiescent cells and in
di¡erentiated cells, whereas it is down-regulated as the cells
enter the growth cycle. This gene was ¢rst identi¢ed as a
translocation gene in a case of B cell chronic lymphocytic
leukemia [3,22]. The mRNA is 1.8 kb long. AP-1-like se-
quence is located in the promoter region of APRO2 gene to
react to AP-1 activity [23]. By the gene transfection experi-
ment, it was shown that APRO2 negatively regulates cell pro-
liferation. APRO2 displayed a di¡use cytoplasmic localization
in con£uent cells, whereas a major nuclear localization
in proliferative cells in some condition, suggesting that
some pathway could drive the translocation of APRO2
into the nucleus [23]. It was shown that Xenopus APRO2
was expressed in the prospective mesoderm and overexpres-
Fig. 1. Comparison of the schematic structure of the predicted APRO protein family members. The human chromosomal mappings of the
genes are also shown. Numbering of the APRO is arranged in order of protein length of the respective gene product. The original names used
in the published paper or in the gene bank account are shown on the right.
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sion of the APRO2 prevented gastulative movements in em-
bryos.
2.3. APRO3 (Pc3k, Pc3b)
Isolation of APRO3 gene has been reported most recently
[9]. This gene is also endowed with marked anti-proliferative
activity resulting in G1 arrest. The mRNA is 1.4 kb long. Its
expression is high in testis, in oocyte and in the olfactory
epithelium at midgestation, suggesting involvement in gameto-
genesis and neuronal di¡erentiation.
2.4. APRO4 (Btg3, Ana)
It has been reported that the APRO2 and APRO4 are
highly expressed in neuroepithelium near the lateral ventricle
[7]. However, it seems that this expression is ubiquitous with
variations between di¡erent tissues. The mRNA is 1.5 kb
long. The RNA level of APRO4 peaks at the end of G1 phase
of cell cycle [6], and the expression is inducible in cultured
cells by redox changes [19]. Immunohistochemical studies
have described APRO4 as a cytoplasmic protein [7]. Although
APRO4 also physically interacts with Caf1, APRO4 does not
interact with PRMT1 [24]. In a certain condition, APRO4
might associate with BANP, a novel nuclear protein [24].
2.5. APRO5 (Tob2, Tobr)
APRO5 was isolated as a related sequence to APRO6 gene
by means of a RT-PCR-mediated procedure [8]. The mRNA
is 4.1 kb long and ubiquitously expressed in adult tissues
(relatively high in skeletal muscle and in oocytes). The gene
is mapped to human chromosome 22q13.1^q13.31. APRO5
seems to function as an association molecule to Caf1, and
exogenous expression of APRO5 inhibits G1 progression of
the cells [8].
2.6. APRO6 (Tob, Tob1)
APRO6 gene was initially identi¢ed by screening an expres-
sion library to seek for an interaction molecule with ErbB2, a
receptor tyrosine kinase [4]. The APRO6 gene is ubiquitously
expressed and the mRNA is 2.3 kb long. Recently, it has been
proved that APRO6 is associated with Smads to control os-
teoblast-growth [25]. It was also shown that the mice lacking
the APRO6 gene frequently developed osteopetrotic pheno-
type [25]. Furthermore, APRO6 seems to be phosphorylated
and regulated by Rsk1, a protein kinase functioning down-
stream MAPK [26].
3. Implication of APRO family genes in biological processes
Several arguments suggest that these genes have mainly a
role in the negative control of the cell cycle. First of all, there
is a correlation between their level of expression and the dif-
ferent phases of the cell cycle. In various models, APRO1 and
APRO2 are strongly expressed in the phases G0/G1 of quies-
cence of the cell cycle [3,11,23,27,28]. APRO4 is detected
rather in G1/S phase [6]. Besides, the addition of prostaglan-
din E2 inhibits the proliferation of macrophages and enhances
APRO2 expression [29]. It was also shown that variations of
expression of the APRO genes accompanied di¡erent events
linked to the cell di¡erentiation. Several experiments have
established a link between APRO1 and neurogenesis. It was
described that APRO1 was expressed during the phase G1 of
the cell cycle in neuroepithelial cells which were going to gen-
erate a neuron after their next mitosis [27,30,31]. It is neces-
sary to note that the gene APRO1 was initially isolated as
being induced by the NGF in PC12 cells and that APRO3
is strongly expressed in the olfactory epithelium [1,9]. The
APRO2 role was studied during gametogenesis where it
reaches a maximal expression in spermatids [32]. APRO5 is
strongly expressed in ovocytes [8]. Con¢rming the hypothesis
of a role of the APRO family during the sexual di¡erentiation,
FOG3, the only representative of the family in Caenorhabditis
elegans, was involved in the sexual determinism of this organ-
ism [33]. Another study showed a modi¢cation of APRO2
Fig. 2. Phylogenetic relationship in the APRO family. An evolution-
ary tree with the signi¢cantly correlated sequences based on the
alignment of the APRO conserved region (101 residues) was calcu-
lated with the nearest-neighbor-joining algorithm (distance PAM).
The evolutionary distance is shown by length of the horizontal line
segments. The gene name/species/accession number/alternative name
are follows: Btg2/Pc3 human U72649 (Btg2); Btg2/Pc3 mouse
M64292 (Tis21); Btg2/Pc3 rat M60921 (Pc3); Btg2 Danio rerio
AB036784; Btg1 human X61123; Btg1 bovine AF014008; Btg1
chicken X64146; Btg1 Xenopus AJ009283; Btg1 mouse Z16410;
Btg1 rat L26268; Btg3 human D64110; Btg3 rat AF087037; Btg3
mouse Z72000 (tob5); Pc3b mouse AJ005120; Pc3k human
AJ271351; B910 Xenopus X73317; B915 Xenopus X73316; Tob
Fugu rubripes AL017231; Tob human D38305; Tob mouse D78382;
Tob2 human AB035207; Tob2 mouse AB041225; Tob Amphioxus
U95824; Tob Drosophila melanogaster AF177464; FOG3 Caeno-
rhabditis elegans Z81033 (C03C11.c)
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expression during myogenesis with an increase of its expres-
sion during the phase of di¡erentiation of myoblasts into
myotubes [23,34]. Finally, xBTG1 (Xenopus) and Amphitob
(Amphioxus) play a role in the control of the embryonic de-
velopment of these animals [5,35]. On the other hand, several
experiments showed that the forced expression of these genes
(APRO1, APRO2, APRO3, APRO4, APRO5, APRO6) was
more or less anti-proliferative [3,4,7^9,18,35,36]. Furthermore,
CAF1, a transcription factor partner of APRO proteins
presents also this characteristic [37]. It is interesting to note
that CAF1, perhaps in association with APRO1, would reg-
ulate negatively the expression of cyclin D1 ([38], our unpub-
lished data). Conversely, APRO1 deleted cells do not stop
proliferating when they are subjected to conditions such as
control cells would arrest [11]. Besides, in di¡erent models,
a link seems to exist between the APRO gene expression level
and the proliferation. A study showed that the expression of
APRO2 was higher in androgen-dependent prostate cancer
cell line than in cell line independent from hormones which
are more invasive [39]. APRO1 would be associated too to a
lesser aggressiveness of the tumors which express it [40]. Fi-
nally, a loss of APRO1 expression was correlated with the
development of tumors into SV40 T transgenic mice [41].
APRO genes are also induced in various situations of stress
being able to lead to a cell cycle arrest or even to the apopto-
sis: APRO2 in macrophages loaded with lipids [36], APRO1
and APRO4 by an oxidative stress [17], APRO1, APRO2 and
APRO6 by a genotoxic stress [42], APRO1 by a membrane
depolarization, an acute pancreatitis, a kidney ischemia, a
neonatal hypoxia or an electroconvulsive shock [1,43^46]. Fi-
nally, APRO1 was shown to be involved in biochemical path-
ways leading to apoptosis [47,48]. It is noteworthy that the
expression of APRO1 is regulated by the tumor suppressor
gene p53 [11,41]. So, the induction of p53 activity consecutive
to a stress leads to APRO1 upregulation what would ¢nally
induce the cell cycle arrest. Recently, it has been shown that
APRO6 gene-de¢cient mice have a greater bone mass resulting
from increased number of osteoblasts, suggesting that APRO6
is a physiological regulator of proper osteoblast proliferation
[25]. As expression of APRO5 (a close homolog of APRO6)
was very low in osteoblasts, the phenotype of the APRO6-
de¢cient mice seemed be conspicuous in the bone without
redundant e¡ect. So far, APRO genes seem to be involved
in the negative control of the cell cycle in particular during
cell di¡erentiation and this frame allowed at least to give a
possible explanation for these various observations. In the
next paragraph, we are going to try to understand the bio-
chemical nature of these phenomena.
4. Downstream e¡ectors
APRO1 expression is regulated by p53, and its inactivation
in embryonic stem cells leads to the disruption of DNA dam-
age-induced cell cycle arrest [11]. These observations raise the
question whether APRO1 may promote p53-induced cell cycle
arrest similar to p21Cip1. The involved molecular mechanisms
have again little known. However, the demonstration of a link
with cyclin D1 allows a better understanding of the biochem-
ical pathways [38]. Indeed, several works had shown that the
overexpression of members of the APROs (APRO1, APRO5
or APRO6) family was accompanied by Rb hypophosphory-
lation [8,18]. Rb under its hypophosphorylated form seques-
ters factors of transcription, E2F in particular, and in this way
prevents the transcription activation of genes necessary to the
pursuit of the cell cycle. These Rb phosphorylations are cata-
lyzed by CDK/cyclin complex of variable composition de-
pending on the phases of the cell cycle. To understand if the
Rb hypophosphorylation observed following APRO1, overex-
pression was attributable to the particular de¢ciency of a
CDK/cyclin complex, cyclins were expressed in cells along
with APRO1; only the cyclin D1 was able to counteract the
APRO1 mediated cell cycle arrest [38]. APRO1 exhibits a
transcriptional inhibition on the cyclin D1 promoter that
leads to the observed decreased kinase activity of the
CDK4/cyclin D1 complex. These ¢ndings indicate that
APRO1 acts as a transcriptional regulator of cyclin D1 and
then impairs G1-S transition by inhibiting Rb function in the
consequence of a reduction of cyclin D1. Furthermore, this
impairment could be ¢nally mediated by CAF1, what would
explain the anti-proliferative e¡ect of several members of the
APRO family (our unpublished results of the analysis of
CAF3/3 cells). It should be noted that CAF1 has recently
been shown to belong to a deadenylase complex [60]. So,
regulation of RNA stability could also be implicated in cell
Fig. 3. The outlined involvement of APROs in the biological and biochemical processes.
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cycle control. A physical interaction of APRO1 with CDK1,
as well as with CDK4 was also observed [38]. As a functional
consequence, one can imagine that APRO1 overexpression
modi¢es the activity of the CDK4/cyclin E complex, which
were critical for a G1-S transition in cell cycle, as observed
by Lim and co-workers in their cellular model [49]. Another
important observation allowing a better understanding of
these mechanisms is that APRO1 and APRO2 interact with
PRMT1 and control its activity [50]. 90% Of this activity of
type 1 is due to PRMT1. Furthermore, PRMT1 expression
has a fundamental role since PRMT13/3 mice are not viable
and die in utero [51,52]. Methylation of proteins is a post-
translation modi¢cation of a presently unknown role but that
could be involved in the transduction of anti-proliferative sig-
nals [53]. Indeed, it was shown that an inhibition of this meth-
ylation prevented the di¡erentiation of PC12 cells under the
in£uence of NGF [54]. Furthermore, an increase of the cellu-
lar methyltransferase activity was observed simultaneously to
the induction of the expression of APRO1 and APRO2 by
genotoxic treatments [42]. PRMT1 also interacts with IF-
NAR1 (intracytoplasmic chain of the interferon receptor)
[55]. This observation brings a supplementary element in
PRMT1 implication in the negative control of the cell cycle
because cells where PRMT1 activity was invalidated by anti-
sense oligomers, do not stop to proliferate under the in£uence
of the interferon contrary to control cells [55]. Recently, it has
been demonstrated that this inhibition arose from impaired
STAT1 function in the absence of arginine methylation [61].
Discovery of PRMT1 targets and of the consequence of the
methylation on their activity is now the goal to achieve. One
of the most interesting results at present is that PRMT1 is a
co-factor belonging to a transcription complex including
among others the nuclear receptors of hormone [56,57].
Thus, the methyltransferase activity regulated by APRO1
and APRO2 could be consequently integrated at this level.
Another element which can explain the role of APRO1 and
APRO2 in the control of the cell cycle and of the di¡erentia-
tion is their association with HOXB9 [58]. APRO1 and
APRO2 enhance HOXB9-dependent transcription. HOXB9
is thought to regulate the transcription of NCAM. This latter
is involved in the neurogenesis and its overexpression is anti-
proliferative. APRO1 and APRO2 are supposed to enhance
¢nally its expression and this could explain some e¡ects elic-
ited by APRO1 and APRO2 [58]. The expression of xBTG1
(Xenopus) is regulated by xBRA (Xenopus homolog of Brad-
chyuary) and Pintallavis. The authors show that xBTG1 over-
expression in whole embryos impairs the gastrulation and
would be anti-proliferative [35]. APRO6 was initially isolated
as an interaction molecule to ErbB2 kinase, however, the sig-
ni¢cance of the binding needs to be clari¢ed further. Recently,
APRO6 has been shown to act as a negative regulator of
Smad signaling in osteoblasts. They showed that APRO6 as-
sociated with receptor-regulated Smad1, Smad5, Smad8 and
co-localized with these Smads in the nuclear bodies after bone
morphogenetic protein (BMP) stimulation. These data clearly
suggest that APRO6 is a novel inhibitor of BMP/Smad signal-
ing. These observations link APROs to an already known and
studied pathway. So, it should allow us to establish its func-
tion more exactly in order to understand cell cycle regulation
by APROs.
5. Perspective
A better understanding of the APROs involved in the reg-
ulation of cell growth is now emerging. It seems likely that the
main points for the control are in the cell cycle, however, the
process to the resultant phenomenon with cell cycle inhibition
mostly during cellular di¡erentiation seems to include some
di¡erent e¡ector pathways. This could also explain the appar-
ent overlapping and sometimes di¡ering functions of APROs.
Now, we have a simple question. What is the common cellular
process mediated through APRO homology domain in re-
sponse to various stimulation? In other words, given that
the APRO protein family is characterized by the presence of
two conserved boxes (APRO homology domain) in their ami-
no terminus, what is the most important physiological and
biochemical function by the APRO domain? It may be plau-
sible that interaction of the APRO family with Caf1 may
a¡ect a variety of transcriptional machineries involved in
cell proliferation [59]. Furthermore, it should be noted that
APRO proteins could play a role in RNA regulation: Caf1
has recently been shown to be involved in a deadenylase com-
plex and PRMT1-mediated arginine methylation is thought to
interfere with RNA/protein association. Various powerful ex-
perimental approaches could guide further exploration of the
involved proteins and pathways in order to de¢ne more pre-
cisely if they constitute the elements of a novel signaling path-
ways.
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